<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="459">
  <stage>Registered</stage>
  <submitdate>7/07/2004</submitdate>
  <approvaldate>7/07/2004</approvaldate>
  <nctid>NCT00086658</nctid>
  <trial_identification>
    <studytitle>Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)</studytitle>
    <scientifictitle>A Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- Sparing Effects of Mepolizumab in Subjects With Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of Subjects With HES</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>100185</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypereosinophilia</healthcondition>
    <healthcondition>Hypereosinophilic Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - mepolizumab

Treatment: drugs: mepolizumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of subjects who achieve a total daily prednisone dose of &lt;/=10 mg for a period of 8 consecutive weeks</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the effect of mepo in lowering prednisone dose and blood eosinophil count, improving HES-associated skin manifestations, improving quality of life (QoL), safety and tolerability.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Documented history of Hypereosinophilic Syndrome (HES)

          -  Eosinophil count greater than 1500 cells for 6 months

          -  Signs and symptoms of organ system involvement

          -  No evidence of parasitic, allergic or other causes of eosinophilia after comprehensive
             evaluation.

          -  Achieve and maintain a stable prednisone (corticosteroid) dose prior to starting study
             medication.

          -  Not pregnant or nursing.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Churg-Strauss Syndrome

          -  Wegener's Granulomatosis

          -  Lymphoma, hematological malignancy, advanced and metastatic solid tumors

          -  Chemotherapy, radiotherapy or interleukin 2 treatment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>86</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>GSK Investigational Site - St Leonards</hospital>
    <hospital>GSK Investigational Site - South Brisbane</hospital>
    <hospital>GSK Investigational Site - Melbourne</hospital>
    <hospital>GSK Investigational Site - West Perth</hospital>
    <postcode>2065 - St Leonards</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>3050 - Melbourne</postcode>
    <postcode>6005 - West Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Suresnes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bayern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Niedersachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schleswig-Holstein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Hypereosinophilic syndrome (HES) is a rare disease with broad clinical signs and symptoms
      which is diagnosed based on a persistent blood eosinophil count of greater than 1500 cells,
      various end-organ damages (including skin, heart, lung, nervous system and digestive system
      etc.), and with exclusion of known secondary causes of hypereosinophilia.

      HES has a high morbidity/mortality rate. The major treatment of HES has been systemic
      corticosteroid and other chemotherapeutic drugs (for example, hydroxyurea and interferon)
      with the intention to lower eosinophil counts and therefore to slow down the progression of
      disease. Even though corticosteroid and other therapies can effectively reduce eosinophilia
      in some patients, some may eventually become nonresponsive and intolerable to the amount of
      side effects of the long-term therapy with these medications.

      Mepolizumab is a humanized monoclonal antibody that binds specifically to human interleukin 5
      (hIL-5) and inhibits its activity. Previous human experience has shown it has been effective
      in reducing blood eosinophilia in atopic and HES patients and has alleviated some HES
      clinical signs and symptoms. This study intends to further evaluate the
      corticosteroid-sparing and clinical benefit of mepolizumab in HES.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00086658</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>